leadf
logo-loader
RNS
viewMaxCyte Inc

MaxCyte, Inc. - Appointment of Amanda L. Murphy as CFO

RNS Number : 3947Y
MaxCyte, Inc.
09 September 2020
 

 

 

 

 

 

MaxCyte Appoints Amanda L. Murphy as Chief Financial Officer and

Names Ron Holtz as Senior Vice President & Chief Accounting Officer

 

-     Murphy brings a wealth of life sciences capital markets experience and deep knowledge in the enabling technologies and cell therapy sectors

-     Holtz to remain on the Board of Directors of the Company and retain key elements of his executive role, including overseeing accounting, budgeting, and supporting key business operations

 

Gaithersburg, Maryland - 9 September 2020: MaxCyte, Inc. (LSE: MXCT, MXCL), a global cell-based therapies and life sciences company, announced today that Amanda L. Murphy, CFA, has joined the Company as Chief Financial Officer (CFO). Ron Holtz, who has served as MaxCyte's CFO since 2005, will become Senior Vice President and Chief Accounting Officer (SVP & CAO).

 

Before joining MaxCyte, Ms. Murphy served as a Managing Director of BTIG, LLC. She has specialized in gene therapy, gene editing and cell therapy equity research for both burgeoning private and established public healthcare companies. Prior to BTIG, she was a Partner and Healthcare Analyst at William Blair & Company, focused on diagnostic services and life sciences. She received a BS in biology from Boston College's honors program, and an MBA in finance, accounting and economics from the Kellogg Graduate School of Management at Northwestern University.

 

MaxCyte President & CEO, Doug Doerfler, said: "We are extremely pleased to welcome Amanda, who served as a successful, respected analyst in both the enabling technology and cell therapy sectors, to the MaxCyte team at this pivotal moment for the Company and the industry. We are collectively witnessing the beginning of cell and gene therapies' impact on revolutionizing medical treatment and saving human lives, and Amanda's wealth of experience - her deep understanding of the financial community and her unique, insightful, strategic view of the cell therapy sector - will support the continued development and expansion of MaxCyte's contribution in this space."

 

Ms. Murphy commented, "From my work as a healthcare analyst, I've long been familiar with MaxCyte's central role in the cell therapy space, as the inventors of the premier cell engineering enabling technology and the go-to partner for the world's leading gene editing and cell therapy companies. It's exciting to join MaxCyte at this time, as the cell therapy industry continues to accelerate the development of advanced life-saving therapies, and as the Company looks to evolve its business model with the spin-off of CARMA Cell Therapies™ and a potential listing on the Nasdaq exchange."

 

In his new role as CAO and SVP, Ron Holtz, will retain key elements of his former role as CFO, including overseeing accounting and budgeting/forecasting and supporting key business operations. The Board of Directors is unchanged with Mr. Holtz remaining as an Executive member of the Board.

 

Mr. Holtz noted, "As MaxCyte grows, evolves, and prepares for entry into the US public equity market, it's the ideal time for us to bring in someone with Amanda's unique capital markets perspective and deep insights into the cell tharapy space.  I am also looking forward to continuing to focus where my primary interests and skillsets can best support MaxCyte's future."

 

About MaxCyte

MaxCyte is a clinical-stage global cell-based therapies and life sciences company. As the inventors of the premier cell-engineering enabling technology, the Company helps bring the promise of next-generation cell and gene-editing therapies to life. The Company's technology is currently being deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licences have been granted for more than 120 cell therapy programmes, with more than 90 licensed for clinical use, and the Company has now entered into eleven clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998, is listed on the London Stock Exchange (LSE: MXCT, MXCL) and is headquartered in Gaithersburg, Maryland, US. For more information, visit www.maxcyte.com.

###

 

 

Contacts:

 

MaxCyte Inc.

Doug Doerfler, Chief Executive Officer

Amanda Murphy, Chief Financial Officer

 

+1 301-944-1660

Nominated Adviser and Joint Corporate Broker

Panmure Gordon

Emma Earl

Freddy Crossley

Corporate Broking

James Stearns

 

 

+44 (0)20 7886 2500

Joint Corporate Broker

Numis Securities Limited

James Black

Duncan Monteith

 

 

+44 (0)20 7260 1000

 

Financial PR Adviser

Consilium Strategic Communications

Mary-Jane Elliott

Chris Welsh

 

--------------------------------------------------------------

 

+44 (0)203 709 5700

maxcyte@consilium-com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAUWRBRROUKRAR

Quick facts: MaxCyte Inc

Price: 402

Market: AIM
Market Cap: £310.18 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

MaxCyte Inc: Analyst talks expansion of its phase I clinical trial of MCY-M11

Proactive Research analyst Emma Ulker discusses the update this morning from MaxCyte Inc (LON:MXCT) on the expansion of its phase I clinical trial of MCY-M11 - its differentiated lead cell therapy candidate currently in first-in-human studies for advanced solid cancers. Ulker says the move is a...

on 18/8/20

5 min read